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ABSTRACT
Context Computerized drug alerts for psychotropic drugs
are expected to reduce fall-related injuries in older
adults. However, physicians over-ride most alerts
because they believe the beneﬁt of the drugs exceeds
the risk.
Objective To determine whether computerized
prescribing decision support with patient-speciﬁc risk
estimates would increase physician response to
psychotropic drug alerts and reduce injury risk in older
people.
Design Cluster randomized controlled trial of 81 family
physicians and 5628 of their patients aged 65 and older
who were prescribed psychotropic medication.
Intervention Intervention physicians received
information about patient-speciﬁc risk of injury computed
at the time of each visit using statistical models of non-
modiﬁable risk factors and psychotropic drug doses. Risk
thermometers presented changes in absolute and
relative risk with each change in drug treatment. Control
physicians received commercial drug alerts.
Main outcome measures Injury risk at the end of
follow-up based on psychotropic drug doses and non-
modiﬁable risk factors. Electronic health records and
provincial insurance administrative data were used to
measure outcomes.
Results Mean patient age was 75.2 years. Baseline risk
of injury was 3.94 per 100 patients per year.
Intermediate-acting benzodiazepines (56.2%) were the
most common psychotropic drug. Intervention physicians
reviewed therapy in 83.3% of visits and modiﬁed therapy
in 24.6%. The intervention reduced the risk of injury by
1.7 injuries per 1000 patients (95% CI 0.2/1000 to 3.2/
1000; p¼0.02). The effect of the intervention was
greater for patients with higher baseline risks of injury
(p<0.03).
Conclusion Patient-speciﬁc risk estimates provide an
effective method of reducing the risk of injury for high-
risk older people.
Trial registration number clinicaltrials.gov Identiﬁer:
NCT00818285.
INTRODUCTION
Injuries are among the leading causes of morbidity
and mortality in older adults.
1 2 The majority of
injuries are fall-related, and 5e10% are fatal.
3e5 A
further 9e27% lead to a permanent loss of capacity
for independent living.
26Psychotropic drugs are
a potentially preventable cause of injury.
7e13 These
drugs are commonly used in older adults, often for
indications, such as insomnia and pain, where
strong evidence of efﬁcacy is lacking.
14e16 Based on
systematic reviews, the risk of injury is increased
by 39%, 59%, and 50% with the use of benzodi-
azepines, antidepressants, and antipsychotics,
respectively.
7 Risks appear to be dose-dependent,
particularly for antipsychotics and opioids, where
the most rapid increase in use is seen for older
adults.
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Effective management of psychotropic medica-
tion is challenging. In older adults, 21e33% of
prescribed psychotropic medication is relatively
contraindicated,
20e22 and 29% in doses that exceed
those recommended.
22 Moreover, 20% of older
adults use more than one psychotropic drug
concurrently, and 69% have more than one physi-
cian prescribing treatment, increasing the risk of
undetected cumulative toxicity.
23
Computerized prescribing and decision support
are expected to address preventable medication
errors, as these digital technologies can guide dosing
and provide alerts on drug treatment duplication,
contraindications, and drug interaction errors, espe-
cially when integrated with information on all
dispensed medication. However, the majority of
drug alerts are over-ridden, particularly for psycho-
tropic medication
24e27 in both hospital-based and
community-based studies. Even when drug alert
systems are customized to present only clinically
important interactions, physicians over-ride the
majority of alerts, because they are deemed not
clinically relevant and/or the beneﬁt is believed to
exceed the risk.
24e26 28 29 Yet, the patient-speciﬁc
risk is rarely known, even though it can be estimated
by incorporating into drug alert systems predictive
models of adverse events developed through phar-
macoepidemiological studies.
30 The advanced
computing power available in today’se l e c t r o n i c
record systems and the focus on individualized
medicine provides an unprecedented opportunity
to integrate detailed patient data into complex
predictive models for estimating patient risk.
In this study, we tested the hypothesis that the
incorporation of patient-speciﬁc risk estimates
into a computerized prescribing decision-support
system in primary care would increase physician
response to alerts for psychotropic medication and
reduce the risk of psychotropic drug-related injury
in older adults, particularly for patients with
a higher baseline risk.
METHODS
Context
The study was conducted in Quebec, Canada,
a province with 8.5 million residents and 16000
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Research and applicationsphysicians. The provincial insurance agency (RAMQ) provides
health insurance for all provincial residents, and pays all physi-
cians and community pharmacies on a fee-for-service basis.
Beneﬁciary, medical billing and pharmacy claims data can be
used to create longitudinal health histories for each patient.
These data have been validated and are often used for health
services and epidemiological research.
31e34 In 2003, MOXXI, an
experimental community-based clinical information system,
was the ﬁrst to link to these databases and integrate this
information into electronic health record systems to support
clinical decision-making.
35
Design and study population
A cluster randomized controlled trial was conducted to test the
hypothesis that prescribing decision support that provided
patient-speciﬁc risk assessment would reduce the risk of injury in
older adults. The trial was conducted in a population of 81
family physicians and 5628 of their older patients from
September 2008 to July 2010. This sample size was expected to
detect a difference in risk of 5% assuming 80 physician clusters,
50 patients per physician, a cluster correlation of 0.01, and a Type
I and II error of 5% and 20%, respectively. Injury risk reduction
was assessed at the end of the follow-up period (July 2010).
Potentially eligible physicians were identiﬁed from the roster
of active primary care physicians in the Quebec provincial
regulatory authority and invited to participate in the MOXXI
primary care research network to evaluate the use of comput-
erized drug and chronic disease management systems in primary
care.
14e16 27 36 37 To be enrolled in the network, physicians
needed to practice actively in an urban community setting in
Montreal or Quebec City, and use the computerized drug
management system successfully to write a minimum of 10
patient prescriptions per week.
Patients were eligible if they were age 65 years or older, had an
active dispensed prescription for a psychotropic drug, or were
prescribed a new psychotropic drug at a visit during the follow-
up period. Psychotropic drugs included those with central
nervous system side effects that increased the risk of injury:
benzodiazepines, antidepressants, antipsychotics, anticonvul-
sants, antihistamines, and opiates.
38
Randomization and blinding
To optimize balance in the intervention and control group, we
stratiﬁed physicians by the number of patients in their practice
who were prescribed psychotropic medication in the past year,
with a minimum of two physicians per stratum. Within each
stratum, an equivalent number of physicians were randomized
by the biostatistician to intervention and control groups
using a random number table. Physicians were not blinded to
the intervention status, but were blinded to the speciﬁc
study outcomes that were measured. Unless advised by their
physicians, patients were blinded to the intervention status.
Intervention and control group
Both the intervention and control groups used the MOXXI
community-based clinical information system (CIS). A link to
the provincial insurance agency (RAMQ) was used to pre-
populate demographic information for the practice population
based on a study physician’s billings from the previous year. For
patients who consented to participate in the research network,
all medical services and prescription drugs provided for the past
year were loaded into the MOXXI CIS, and thereafter all new
records of medical services and prescriptions were refreshed on
a daily basis. These data were used to update the proﬁle of
dispensed medications, dates and reasons for emergency depart-
ment visits and hospitalizations, medical and surgical proce-
dures, and health problems.
39 40 A commercial drug alert system
(http://www.vigilance.ca) automatically reviewed each new
prescription for potential contraindications, including therapy
duplication, dosing error, cumulative toxicity, and drugedisease,
drugedrug, and drugeallergy interactions. Physicians could set
the threshold for the alert system to one of three levels (1, severe
alerts only; 2, moderate and severe alerts; 3, all alerts), which
restricted alerts generated automatically during the prescribing
process. By default, the system was set to level 2. However, all
alerts generated for a patient were available for the physician to
review in a drug alert summary in the patient’s electronic chart.
Physicians randomized to the control and intervention groups
had access to these standard features of the MOXXI CIS.
Physicians randomized to the intervention group received
apatient-speciﬁcriskofinjuryalertwhenapatientwasprescribed
a psychotropic medication that increased the risk of injury. The
personalized alert useda published predictive model
38 to estimate
the risk of injury based on the patient’s age, sex, injury history,
presenceofcognitiveimpairment,gait,andbalanceproblems,and
doses of selected psychotropic medication (selective serotonin /
nor-epinephrine reuptake inhibitors antidepressants, antipsy-
chotics, low-, intermediate- and high-potency opiates, interme-
diate- and long-acting benzodiazepines, anticonvulsants, and
ﬁrst-generation antihistamines
41 42). We set a relatively low
threshold for showing the alertdan increase in risk of 1 per
1000dto enable us to assess the likelihood of changes in drug
treatment as a function of the magnitude of patient risk.
Graphics, in the form of risk thermometers, were created to
show physicians the patient’s risk of injury in the next
12 months related to psychotropic medication as well as non-
modiﬁable characteristics (eg, age, sex) (ﬁgure 1A). Physicians
would see the risk thermometer, annotated with numeric values
generated by the risk calculation described above, when they
opened the patient drug proﬁle or when they prescribed
a psychotropic drug. Drugs that contributed to the risk calcu-
lation were highlighted in the patient’s drug proﬁle. If the
physician attempted to reduce the risk of injury by stopping or
decreasing the dose of a psychotropic medication, the absolute
and relative reduction in risk would be shown as an adjustment
in the level of the thermometer and a change in the numeric
values (ﬁgure 1B). If a new psychotropic drug was started or the
dose was increased, the absolute and relative increase in the risk
would be shown (ﬁgure 1C). If no change in medication was
instituted (or the risk was increased by a medication change),
physicians had to select a reason for the decision from a stan-
dardized pick-list (eg, prescribed by another physician). A refer-
ence section was available with publications on the risk of injury
related to psychotropic drug use and methods of tapering
benzodiazepines.
Physicians in the intervention group received a 5-minute
training program on the risk of injury alert that outlined how to
interpret the risk thermometer information, the expected
changes in risk with new or discontinued medication, the
completion of reasons for not changing therapy if applicable,
and the location of reference information. Physicians were
advised that stopping or reducing the dose of highlighted
medications in the patient’s drug proﬁle would reduce the
patient’s risk of injury.
Physician characteristics
Physician age, sex, and years of practice experience were docu-
mented at enrollment. Annual measures of practice size, number
636 J Am Med Inform Assoc 2012;19:635e643. doi:10.1136/amiajnl-2011-000609
Research and applicationsFigure 1 (A) Screenshot of the user interface for the ‘risk of injury alert’ showing current risk and lowest possible risk. (B) Screenshot of the user
interface for the risk of injury alert showing a reduction in risk due to modiﬁed treatment. (C) Screenshot of the user interface for the risk of injury alert
showing risk increase with modiﬁed treatment.
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Research and applicationsof practice settings, workdays, and daily practice volume
were calculated for the year before randomization from each
physician’s RAMQ billing data using methods developed
previously.
40 43 Utilization of the drug management component
of the MOXXI CIS was measured by calculating the number of
electronic prescriptions written per 100 patient visits billed in
the year before randomization. Skill in using the prescribing
system was assessed by timed assessment of prescribing speed
for four standardized prescriptions 3 months after the initial
training for the MOXXI CIS.
Patient characteristics
Patient age, sex, and residential address were documented at
enrollment from the RAMQ insurance records. Residential
address was linked to neighborhood-level Statistics Canada
census information to obtain estimates of patient household
income, classiﬁed by low- (<$31753), middle- ($31754e
$80000) and high- (>$80000) income neighborhoods. Relevant
comorbidity was measured using diagnostic and procedure codes
in RAMQ billing claims and the electronic health record problem
list for each patient. Injury history was assessed by calculating
the number of temporally distinct episodes of billing claim
treatments for fractures and soft-tissue injuries in the past
24 months using algorithms that were previously validated.
32
Cognitive impairment and gait and balance problems were
deﬁned in accordance with International Classiﬁcation of Disease
Ninth Revision (ICD9) codes included in the predictive model
for injury.
38 Cognitive impairment included dementia (291),
alcohol-related cognitive impairment (292), and Alzheimer’s and
other cerebral degeneration (331). Gait and balance problems
included degenerative diseases of the extrapyramidal system
(332333), seizure disorders (345), vertiginous syndromes (386),
syncope (780), and orthostatic hypotension (458). The Charlson
comorbidity index,
44 45 number of emergency department visits,
and number of hospital admissions in the past year were also
measured using RAMQ billing data to provide descriptive
information about population characteristics.
Outcomes
The primary study outcome was the risk of injury at the end of
the follow-up period. To assess whether the effect of the inter-
vention was greater for patients at higher risk, each patient’s risk
of injury was measured twice, once at the patient’s ﬁrst visit
after randomization (baseline risk) and again on the last day of
follow-up (July 15, 2010) for the intervention and control groups
(outcome risk). Overall injury risk was measured using the
predictive model used in the intervention, which reﬂected the
probability of an injury in the next year based on age, sex,
comorbidity, and daily dispensed doses of benzodiazepines,
opiates, antipsychotics, antidepressants, anticonvulsants, and
antihistamines (ﬁgure 2). Drug doses were based on active
dispensed prescriptions on the ﬁrst and last day of follow-up. To
permit multiple drugs within the same therapeutic category to
be combined, doses were standardized, using the same approach
as the predictive model, by dividing the daily dose by the WHO-
recommended daily dose for adults for each drug.
46 For example,
a patient prescribed 20 mg diazepam and 10 mg lorazepam daily
would be using three standardized doses of benzodiazepine
(20 mg diazepam/10 mg (WHO-recommended dose) + 10 mg
lorazepam/10 mg (WHO-recommended dose) ¼ three doses).
In a secondary analysis, we assessed the physician’s response
to the injury risk alert, and changes in the use and dose of
psychotropic medications in the intervention and control
groups. Alert response was retrieved from the MOXXI audit trail
for physicians in the intervention group. The audit trail recorded
each action taken in relationship to psychotropic medication
and its impact on overall and modiﬁable risk. Actions were
classiﬁed into three mutually exclusive categories: (1) over-rode
alert, (2) reviewed options but made no change, and (3) modiﬁed
dose or drug to reduce risk. Reasons for over-riding alerts were
tabulated.
To assess change in use and dose of medication, we estimated
differencesbetweentheinterventionandcontrolgroupsin(1)the
number of active psychotropic medications prescribed or
dispensed, and (2) the standardized dose of psychotropic medi-
cation by therapeutic category between the baseline and follow-
up period. Data were retrieved from records of all medications
dispensedfromthedailyupdatesofthedrugproﬁlebytheRAMQ.
Analysis
To test the hypothesis that the patients in the intervention group
would have a greater reduction in the risk of injury than patients
in the control group, we used multivariate linear regression
within a generalized estimating equation framework. An
exchangeable correlation structure was used to account for clus-
tering of patients within physician. Each patient’s calculated risk
of injury on the last day of follow-up was the continuous
outcome, and experimental status (intervention vs control) was
thepredictor.Thepatient’sbaselineriskscorewasusedtotestthe
hypothesis that the beneﬁts of the intervention would be greater
for high-risk patients. The interaction term between baseline risk
score and experimental status was included in the model, and the
Wald c
2 stxatistic was used to assess statistical signiﬁcance. We
used the same approach to estimate the change in the number of
psychotropic medications and dose by therapeutic category
between the baseline and follow-up period. For medication dose,
we estimated one model per therapeutic category.
RESULTS
Among the 410 physicians eligible, 81 consented to participate,
representing 5628 eligible patients. All consenting physicians
and their patients were included in the analysis (ﬁgure 3).
47
Physicians in the intervention and control groups were
predominantly male, French speaking, and in practice for 25 or
more years (table 1). Physicians in both groups worked, on
average, in 2.2 practice settings, saw 16e17 patients per day, and
used the MOXXI CIS with equivalent frequency and speed of
writing electronic prescriptions.
Patients in the intervention and control groups were similar:
on average 75e76 years of age, predominantly female, and
Figure 2 Formula for estimating the
risk of injury based on individual patient
characteristics.
37 NB Baseline risk was
speciﬁed at 2.06%, representing the
incidence of injury among 65-year-old
men without any other risk factors.
SSRI, selective serotonin reuptake
inhibitors; SSNRI, selective serotonin-
norepinephrine reuptake inhibitors.
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mately 5% of patients had treatment for at least one injury
in the past year, and a similar proportion had cognitive
impairment. The prevalence of gait and balance problems was
slightly higher in the control group as were the proportion of
patients with at least one emergency department visit in the
past year.
At the ﬁrst visit after randomization, the most prevalent
psychoactive medication used was an intermediate-acting
benzodiazepine, taken by approximately one-third of patients,
followed by antidepressants, anticonvulsants, and antipsy-
chotics (table 2). For intermediate-acting benzodiazepines, the
mean daily dose prescribed was 10e20% over the recommended
adult dose, primarily because 4.6% of patients in the control
group and 3.8% in the intervention group were using more than
one intermediate-acting benzodiazepine concurrently. This was
also true for antidepressants, where 1e1.2% of patients were
using more than one antidepressant. The overall risk of injury at
baseline was comparable in the two groupsdthe risk of injury in
the next year was 4.03 per 100 in the control group, and 3.85 in
the intervention group, of which an equivalent amount (control,
0.51; intervention, 0.49) was related to the use of psychoactive
medication. The distribution was skewed, with a median of
3.55, an IQR of 2.88e4.51, and a range 2.09 to 45.30.
Among the 2887 injury alerts generated at the ﬁrst visit for
patients in the intervention group, 13.7% were for new
psychoactive medications that were being started by the
physician during the visit, and the remaining alerts (86.3%) were
for existing medications (table 3). Physicians responded to 2404
(83.3%) risk of injury alerts, by reviewing options but deciding
not to change the treatment (n¼1694, 58.7%), by reducing the
dose, or by discontinuing psychoactive medications (n¼710,
24.6%). Of interest, physicians were more likely to change the
treatment plan for existing medication (25.7%) than for newly
started therapy (17.7%). The most common reason for not
changing treatment was the belief that the beneﬁt would exceed
the risk (n¼1840, 84.5%), followed by patient resistance to
change in therapy (n¼179, 8.2%). While the majority of physi-
cians changed their alert settings from the default setting to
view only the most severe alerts (table 1), there were no
statistically signiﬁcant differences in the alert levels selected by
the control and intervention groups.
On average, patients in the intervention and control groups
were followed for 467 and 452 days, respectively. Although there
Figure 3 Consort diagram of
physicians and patients eligible and
enrolled in the trial.
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Research and applicationswas an overall trend for the number of drugs and doses in all
psychotherapeutic classes (except intermediate-acting benzodi-
azepines) to be reduced in the intervention group, no single class
decreased signiﬁcantly in dose, when modeled alone (table 4).
However, there were signiﬁcant interactions between baseline
risk and intervention status for antipsychotics (interaction term:
p¼0.02) and anticonvulsants (interaction term: p¼0.03),
with reductions in doses occurring for patients with greater
baseline risk. The most prevalent medication affected in these
therapeutic groups was risperidone for antipsychotics (37.5% of
patients (n¼201)) and pregabalin and gabapentin for anticon-
vulsants (71.1% of patients (n¼608)). The most common indi-
cations for prescribing antipsychotics was psychosis/bipolar
disorder (32.2% of patients) and dementia/delirium (20.4% of
patients), and for anticonvulsants it was pain (72.6%).
Congruent with these changes in therapy, the risk of injury in
the intervention group was reduced by 1.7 injuries per 1000
patients (95% CI 0.2/1000 to 3.2/1000; p¼0.02) compared with
Table 1 Characteristics of the 81 physicians and the 5628 patients in
the intervention and control groups
Control, N[40
Intervention,
N[41
Physician demographics N % N %
Sex
Male 20 50.0 22 55.0
Female 20 50.0 18 45.0
Language
English 14 35.0 12 30.0
French 26 65.0 28 70.0
Practice experience (years)
<15 5 12.5 4 10.0
15e24 11 27.5 10 25.0
$25 24 60.0 26 65.0
Practice characteristics Mean SD Mean SD
Annual practice size 1137.4 555.9 1330.6 711.6
Number of practice settings 2.2 1.3 2.2 1.0
Number of clinic days worked 190.6 43.6 186.6 39.1
Number of patients/ clinic day 16.7 7.6 17.4 6.5
Use of MOXXI CIS Mean SD Mean SD
Electronic prescription/100 visits 40.5 28.7 39.2 24.4
Speed in prescription 4 standard scripts (min) 3.08 0.88 3.04 1.09
Minimum alert setting
Level 1 (severe only) 31 77.5 24 58.5
Level 2 (moderate to severe) 5 12.5 12 29.3
Level 3 (all alerts) 4 10.0 5 12.2
Control, N[2741
Intervention,
N[2887
Patient demographics Mean SD Mean SD
Age (years) 75.63 7.47 74.81 6.84
Patient sex N% N %
Female 1876 68.4 1901 65.8
Male 865 31.6 986 34.2
Socioeconomic status
Low income (<$31 753) 868 31.7 790 27.4
Middle income ($31 754e$80 000) 1682 61.3 1918 66.4
High income (>$80 000) 191 7.0 179 6.2
Patient comorbidity
Number injuries past 24 months
No injury 2618 95.5 2766 95.8
1 injury 108 3.9 107 3.7
2 injuries 10 0.4 13 0.5
$3 injuries 5 0.2 1 0.0
Gait or balance problem 505 18.4 476 16.5
Cognitive impairment 150 5.5 130 4.5
Charlson comorbidity index
0 1379 50.3 1565 54.2
1e2 1039 37.9 1048 36.3
3e4 191 7.0 166 5.7
$5 132 4.8 108 3.7
Healthcare utilization
$1 Emergency department visit 1011 36.9 927 32.1
$1 Hospitalization 617 22.5 608 21.1
Table 2 Psychoactive medication at the ﬁrst visit after randomization
Control,
N[2741
Intervention,
N[2887
Distribution by therapeutic class N % N %
Benzodiazepines
Intermediate-acting 1516 55 1648 57
Long-acting 109 4 111 4
Antidepressants 712 26 721 25
Anticonvulsants 451 16 404 14
Antipsychotics 258 9 278 10
Opiates
High potency 22 1 5 0
Intermediate potency 96 4 104 4
Low potency 174 6 195 7
Antihistamines 7 0 4 0
Standardized daily dose among users Mean SD Mean SD
Benzodiazepines
Intermediate-acting 1.20 1.71 1.10 1.52
Long-acting 0.81 0.45 0.74 0.37
Antidepressants 1.04 0.55 1.06 0.58
Anticonvulsants 0.51 0.41 0.54 0.42
Antipsychotics 0.59 2.02 0.79 3.38
Opiates
High potency 0.29 0.85 0.16 0.15
Intermediate potency 0.43 0.38 0.50 0.63
Low potency 0.88 0.77 0.89 0.70
Antihistamines 0.13 0.04 0.79 3.38
Overall use and risk Mean SD Mean SD
Number of psychoactive medications 1.28 0.61 1.25 0.58
Proportion prescribed by study doctor 0.81 0.38 0.78 0.41
Combined standardized dose 1.18 1.59 1.15 1.69
Overall risk of injury 4.03 1.87 3.85 1.70
Risk related to psychoactive medication 0.51 0.80 0.49 1.14
Table 3 Response to the TRIPP alert in the intervention group by type
of prescription
Renewing an
existing
psychoactive
medication
Starting a new
psychoactive
medication
N%N%
Number of alerts 2491 396
Changed prescription 640 25.7 70 17.7
Reviewed but no change 1399 56.2 295 74.5
No review + over-rode alert 452 18.1 31 7.8
Reasons for over-riding alert
Beneﬁt greater than risk 1545 62.02 295 74.49
Patient demand/resistance 161 6.46 18 4.55
Need to consult prescribing doctor 53 2.13 3 0.76
Will review next time 47 1.89 3 0.76
Drug information incorrect 45 1.81 7 1.77
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signiﬁcantly greater for patients at higher risk of injury at
the start of the trial (interaction between the baseline risk of
injury and the intervention: p¼0.03) (ﬁgure 4). For patients in
the upper decile of risk of 5.76, the intervention produced
a reduction in risk of 5.3 per 1000 (95% CI 3.8 to 6.8).
Figure 4 Risk of injury at the end of follow-up in the intervention and control groups and modiﬁcation of the effect of the intervention by the
magnitude of the baseline risk. The model used to estimate the change in the effect of the intervention by baseline risk of injury was: follow-up risk
(y)¼intercept (0.3696) + baseline risk (0.8427) + intervention (0.9585) + baseline risk 3 intervention ( 0.2584) (p¼0).
Table 4 Change in intermediate outcomes: psychotropic drug dose and number of drugs
Intermediate outcomes Dose at the end of follow-up[y]
Dose change[y]
(follow-upL baseline) Cluster adjusted difference[z, x]
Interaction[x]
baseline risk 3
intervention
Dose by therapeutic class[*]
Control Intervention Control Intervention
Difference 95% CI p Value Mean±SD Mean±SD Mean±SD Mean±SD
Benzodiazepines
Intermediate-acting 0.6860.6 0.6660.6  0.7961.7  0.7461.5  0.008  0.05 to 0.03 0.91
Long-acting 0.8860.5 0.7060.3  0.3260.6  0.4360.5  0.006  0.01  to  0.00 0.19
Antidepressants 1.0460.5 1.0760.6  0.4160.8  0.4660.8  0.011  0.03 to 0.01 0.48
Anticonvulsants 0.5160.4 0.5960.4  0.2160.5  0.1960.4 0.006  0.00 to 0.01 0.03
Antipsychotics 0.4460.4 0.5460.7  0.3361.9  0.4963.2 0.005  0.00 to 0.01 0.02
Opiates
Intermediate potency 0.3860.4 0.5660.6  0.2460.5  0.2660.7 0.001  0.00 to 0.01 0.65
Low potency 0.7961.2 0.4960.5  0.6361.0  0.7060.8  0.004  0.01 to 0.00 0.29
By number of psychotropic
drugs
Number drugs at the end of
follow-up
Drug change
(follow-upLbaseline) Cluster adjusted difference
Interaction
baseline risk 3
intervention
Control Intervention Control Intervention
Difference 95% CI p Value Mean±SD Mean±SD Mean±SD Mean±SD
0.6760.8 0.6260.7  0.6060.8  0.6360.8  0.02  0.09 to 0.05 0.96
*There was an insufﬁcient number of patients on high-potency opiates (n¼27) or antihistamines (n¼11) to model separately.
yStandardized drug dosage ¼ daily prescribed dosage (mg)/WHO-recommended adult dosage (mg).
zEach therapy class was modeled separately for drug dose in a model that included baseline dose and intervention group status. To test the hypothesis that the intervention was modiﬁed by
baseline risk, baseline risk was added to the model as well as a two-way interaction term between intervention group status and baseline risk.
xChange in the number of psychotropic drugs was assessed in a model that included baseline number of psychotropic drugs and intervention group status. To test the hypothesis that the
intervention was modiﬁed by baseline risk, baseline risk was added to the model as well as a two-way interaction term between intervention group status and baseline risk.
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This study tested the beneﬁts of using a new approach for drug
safety alerts that provided patient-speciﬁc risk estimates of the
likelihood of harm. The provision of patient-speciﬁc risk infor-
mation resulted in a therapy review in over 80% of patients and
signiﬁcant reductions in the risk of injury related to psychoac-
tive medication, particularly for those who were at greatest risk
of fall-related injuries.
This study produced a greater response to alerts than previous
studies,
24e27 even those that used highly selected subsets of
clinically relevant alerts.
48 49 Not only did physicians review
consequences of revising treatment for the vast majority of
patients, they also modiﬁed drug therapy in one-quarter of
instances.
Of interest, the most common reason for not changing
therapy was that physicians perceived the beneﬁt of treatment
to be greater than the risk. This reason was particularly common
when the patient was starting new medication, possibly because
a physician who starts a patient on medication will generally
have decided that the beneﬁt exceeds the risk before prescribing,
even if the precise risk and beneﬁt are not known. In contrast,
prescription renewals for prevalent users were more likely to be
modiﬁed, possibly because the effects of treatment (or lack
thereof) can be more precisely evaluated, and thus more precise
risk information can be factored into renewal decisions. It may
also be because the evidence supporting the beneﬁts of treat-
ment is less compelling to start with, particularly in some
therapeutic categories. The most signiﬁcant reductions in
therapy in this study were for antipsychotics and anticonvul-
sants, therapeutic categories that have been reported to have
both high levels of off-label use and weak to non-existent
evidence of beneﬁt.
50 Indeed, 22% of anticonvulsant prescrip-
tions were for gabapentin, and all of these prescriptions were for
off-label use for pain.
A ubiquitous complaint about drug alerts is that there are too
many ‘nuisance alerts’, ie, alerts for problems of little clinical
signiﬁcance.
28 49 51 This study is the ﬁrst to identify a data-
driven approach to identifying clinically meaningful alerts and
quantifying the risk associated with an alert. Typically, ‘expert
opinion’ is used to classify alerts as mild, moderate, and severe.
48
This method of classiﬁcation has already been shown to lack
reproducible results so that different commercial systems will
generate different subsets of alerts within these categories.
52 53
Empirically estimating the probability of adverse effects in
different subpopulations provides a more meaningful clinical
metric that could be used to establish alert thresholds. In this
study, physicians were more likely to alter treatment when the
overall risk of injury was high, and, conversely, physicians were
less likely to respond when the risk was low. To study this
effect, the threshold to generate an alert was set at a low level of
risk: an increased risk of 1 per 1000 (0.1%). We identiﬁed the
threshold at which physicians were more likely to respond to an
alert at an overall risk of 32 per 1000 (3 per 100). In the future,
empirical estimates of the risk of adverse outcomes could be
used to establish an alert threshold. Many national agencies
are establishing methods of conducting robust pharmaco-
surveillance. Part of the mandate of post-market surveillance
could be to assess the risk associated with both new drugs and
drug interactions, thereby providing the data needed to establish
and calibrate a new generation of smarter drug alert systems.
An important limitation of drug alerts, including this new
generation of drug alert systems, is that information is presented
only on the risk of treatment and not on the potential beneﬁts.
In the future, efforts should be made to generate empirical
information on both the risks and beneﬁts of treatment, ideally
deriving this information from both clinical trials and post-
market surveillance systems. In addition to providing clinicians
and patients with relative risk and beneﬁt information, ideally
individualized to a patient’s risk proﬁle, alternate treatment
options that have lower risk with equivalent beneﬁt for the
same treatment indication could be provided. Future research
should be directed to methods of generating empirical estimates
of comparative risk and beneﬁt that can be incorporated into
advanced systems of drug decision support, cognitive decision-
making studies that will enable the best methods of presenting
this information to physicians and patients to be identiﬁed,
methods of establishing the threshold for generating drug alerts,
and the potential beneﬁts of displaying alternate therapy
options by treatment indication.
In summary, this study shows that individual risk estimates
displayed graphically and numerically are a more effective
method of eliciting response to drug alerts and reducing the risk
of medication-related injury in higher risk seniors. Future
research should estimate the reduction in injury rate related to
this new generation of alerts and determine whether similar
effects can be achieved in other therapy classes for other
important outcomes.
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